Psoriatic arthritis: interaction between cardiometabolic diseases and inflammatory burden of the disease.

Autor: Lorenzo Martín JA; Hospital Universitario de Burgos, Burgos, Spain. Electronic address: andrew_1_andres@outlook.com., Pardo Campo E; Hospital Universitario Central de Asturias, Oviedo, Spain., Pino Martinez M; Hospital Universitario Central de Asturias, Oviedo, Spain., Colazo Burlato M; Hospital Universitario de Burgos, Burgos, Spain., Queiro Silva MR; Hospital Universitario Central de Asturias, Oviedo, Spain.
Jazyk: angličtina
Zdroj: Reumatologia clinica [Reumatol Clin (Engl Ed)] 2022 Aug-Sep; Vol. 18 (7), pp. 387-392. Date of Electronic Publication: 2021 Nov 17.
DOI: 10.1016/j.reumae.2021.05.003
Abstrakt: Background and Objetives: Psoriatic arthritis is accompained by several cardiometabolic comorbidities. Obesity causes a low-grade systemic inflammation and is a negative predictor of treatment response. We wanted to evaluate if there are interactions between metabolic status, inflammatory parameters and disease activity; and whether metabolic or cardiovascular diseases have any association with the reduction of the inflammatory burden by treating the psoriatic arthritis.
Material and Methods: We have carried out a cross-sectional descriptive study of 160 patients with psoriatic arthritis. Sociodemographic, clinical and analytical variables were collected, as well as the presence of dactylitis and enthesitis; and HAQ, DAPSA and Minimal Disease Activity criteria. Chi-square test and the H of Kruskall Wallis were used to carry out comparisons, considering P < .05 as statistically significant. To establish correlations, Pearson correlation coefficient was used.
Results: BMI and waist circumference correlate with CRP and ESR (significance: < .05) although the correlation strenght is low (Pearson <.4), but there is no such relationship with DAPSA or meeting MDA criteria. Using biologic therapies is associated with a lower prevalence of cardiovascular events (P = 0.047; OR: 0.12, 95% CI: 0.01-0.9) and enthesitis (P = .008; OR: 0.3, CI 95%: 0.16-0.56); and normal levels of CRP (P = .029; OR: 0.25, 95% CI: 0.07-0.87) and ESR (P = 0.024; OR: 0.36, 95% CI: 0.16-0.82) when comparing to conventional therapies.
Discussion and Conclusions: Anti-TNFα treatment could reduce cardiovascular risk in patients with psoriatic arthritis. There may be higher levels of CRP and ESR in obese individuals without this necessarily implying higher disease activity.
(Published by Elsevier España, S.L.U.)
Databáze: MEDLINE
Externí odkaz: